1] Medical Genomics Laboratory, Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA. [2] Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland. [3].
1] Medical Genomics Laboratory, Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA. [2].
Nat Genet. 2014 Feb;46(2):182-7. doi: 10.1038/ng.2855. Epub 2013 Dec 22.
Constitutional SMARCB1 mutations at 22q11.23 have been found in ∼50% of familial and <10% of sporadic schwannomatosis cases. We sequenced highly conserved regions along 22q from eight individuals with schwannomatosis whose schwannomas involved somatic loss of one copy of 22q, encompassing SMARCB1 and NF2, with a different somatic mutation of the other NF2 allele in every schwannoma but no mutation of the remaining SMARCB1 allele in blood and tumor samples. LZTR1 germline mutations were identified in seven of the eight cases. LZTR1 sequencing in 12 further cases with the same molecular signature identified 9 additional germline mutations. Loss of heterozygosity with retention of an LZTR1 mutation was present in all 25 schwannomas studied. Mutations segregated with disease in all available affected first-degree relatives, although four asymptomatic parents also carried an LZTR1 mutation. Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ∼80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1.
在约 50%的家族性和<10%的散发性神经鞘瘤病病例中发现了 22q11.23 处的 SMARCB1 基因突变。我们对 8 名患有神经鞘瘤病的个体进行了沿 22q 的高度保守区域测序,这些个体的神经鞘瘤存在 22q 染色体的一条染色体的体细胞缺失,包含 SMARCB1 和 NF2,而每个神经鞘瘤中的另一个 NF2 等位基因存在不同的体细胞突变,但血液和肿瘤样本中不存在剩余 SMARCB1 等位基因的突变。在 8 个病例中的 7 个中发现了 LZTR1 种系突变。对具有相同分子特征的另外 12 个病例进行 LZTR1 测序,鉴定出 9 个额外的种系突变。在所研究的所有 25 个神经鞘瘤中均存在杂合性丢失,保留 LZTR1 突变。在所有可用的受累一级亲属中,突变均与疾病分离,尽管 4 名无症状父母也携带 LZTR1 突变。我们的研究结果确定 LZTR1 为 22q 相关神经鞘瘤病中约 80%的缺乏 SMARCB1 突变的多发性神经鞘瘤的常染色体显性遗传疾病的易感基因。